Disease And Conditions : Prostate Cancer Causes

Today, prostate cancer is usually detected through screening, and there are two methods for early detection. The prostate-specific antigen test (PSA) is used, but there are

The prostate is a gland in the male reproductive system, about the size of a walnut and surrounds the urethra. One of its main functions is that it produces a fluid that makes up part of the semen. As men age, the prostate may enlarge and expand, and in the enlarged state, it begins to block the flow of urine. This is a symptom of Benign Prostatic Hyperplasia (BPH) and while not cancerous, surgery is required to correct urine flow. Prostate cancer is the most common cancer in men in the United Sates after skin cancer, and it’s the 2nd leading cause of death from cancer in men. Almost all prostate cancer cases are classified as adenocarcinomas, meaning that

There are difficulties and controversy associated with the current screening methods for prostate cancer. The PSA test for prostate cancer has become controversial as it is “not yet known for certain if this test actually does saves lives. It is not clear if the benefits of PSA screening outweigh the risks of diagnostic tests and cancer treatments” (National Cancer Institute, 2009). According to NCI, a PSA test may detect a small amount of cancer that may never become life threatening. This is referred to as over diagnosis and this can put men at risk of complications from any additional and unnecessary treatment (National Cancer Institute, 2009).

In the case for PSA screening, PCa is the leading internal malignancy in US men and the second leading cause of cancer death in American men. Early detection of prostate cancers offers the best chance of cure. The PSA blood test is the best chance of cure. Currently, the PSA blood test is the best currently available way to detect PCa and it is easy, safe and inexpensive. PSA test results is a piece of information, it is what doctors do with the information that becomes the issue. However, the great majority of PSA detected tumors have the histologic characteristics of clinically important cancers. Also, PSA detection has found tumors early advancing the diagnosis by Seeral years (5-13) and prostate cancer mortality rates in U.S have decreased by 4% (patho book) since 1992, which is 5 years after initiation of prostate screenings. The dilemma is over treating the clinically unimportant disease versus under

Prostate Cancer is a disease in which there is an uncontrolled growth of cells that lines the ducts of the prostate gland. The abnormal cells can spread throughout the prostate and nearby organs, such as the seminal vesicles. If not caught early they can spread (metastasized) to other organs of the body through the lymph or blood stream. (“...Treatment...” 13) Prostate Cancer can be like a silent killer. Some may show signs and symptoms of this disease while others may not. Some symptoms may include frequent urination, blood in the urine or semen, delayed or slowed start of urinary stream and dribbling or leakage of urine. Diagnosis testing for Prostate Cancer are digital

Make this November about prostate cancer and raise awareness with “Movember.” Prostate cancer is one of the most common forms of men’s cancer, second to skin cancer. And it is also one of the leading causes of cancer death for men, according to the American Cancer Society. Making medical advice essential this Movember.

Each year approximately 233,000 men will be diagnosed with prostate cancer (Eggener, Cifu, & Nabhan, 2015). In 2015, prostate cancer was the second most common cancer related cause of death among United States men (Eggener, et. al., 2015). While the majority of prostate cancers are slow growing with a 5-year survival rate of approximately 98%, statistics show that when prostate cancer is identified as metastatic, the 5-year survival rate dramatically drops down to 20-25% (Eggener, et. al., 2015). According to these numbers alone, it appears screening for prostate cancer would be a well-accepted practice. However, current methods of screening for this cancer are controversial and has lead organizations like the U.S Preventative Service Task Force (USPSTF) and the American Cancer Society (ACS) to different guidelines for screening.

At the Prostate Cancer Symposium, sponsored by the American Society of Clinical Oncology (ASCO), two leading clinicians and cancer researchers engaged in a point / counterpoint discussion that proved to be illuminating and directional in moving the focus. Though the discussion was themed to create positions of pro versus con, the reality of their arguments really showed more agreement than not.

Prostate cancer is a kind of cancer that affects the prostate gland in men. It is a common cancer that grows slowly and its treatment can be done successfully if it is detected at an early stage. Sometimes, symptoms are not visible in case of cancer limited to the prostate gland which may result into metastatic cancer. To detect the symptoms, active surveillance can be done. There are various options available

Prostate cancer (PCa) is the commonest malignancy tumour in men and is second in cancer related death after lung cancer. PCa is mainly adenocarcinomas originating from the cortex of the gland (D’Elia et al. 2014).

This type of cancer happens in a man's male reproductive gland which is a small walnut-shaped gland that produces the very important fluid that gives food to keep alive and vehicles sperm. Male reproductive gland cancer grows slowly and during the first stages it remains within the male reproductive gland and not be serious or cause any harm. However, while at times male reproductive gland cancer may grow slowly and may only need very little treatment or not treatment at all, there are some type's male reproductive gland cancers that are aggressive and spread quickly. This way identifying a disease or its cause the cancer early while is kept to the male reproductive gland, has a better change of effective treatment. Although there may be no signs and signs of sickness during the early stages of male reproductive gland cancer, when the male reproductive gland cancer is more advance it may cause some signs of sickness including but not limited to; trouble urinating, decreased force in stream of urine, blood in the urine, blood in the semen, swelling of the legs and discomfort in the hip-related area. As of today, it is not certain exactly what causes male reproductive gland cancer among men. It is know that male reproductive gland cancer begins when the cells of the male reproductive gland become different from what's usually expected and change in the DNA of these

Benign prostate hyperplasia (BPH) and prostate cancer share a few similarities, elevated prostate-specific antigen (PSA). Along with enlargement of prostate gland that causes urinary symptoms such as, frequent urination, hesitancy, dribbling, and frequent nighttime urination. However, they are quite different which is why more tests need to be done to confirm one or the other condition. These two diseases are also similar in the fact that they both cause an enlargement of the prostate. However with BPH the central portion of the prostate is enlarged and with prostate cancer more commonly the lateral lobes or side of the prostate are enlarged, but can affect any were on the prostate. Both can even be detected by a digital rectal exam however

According to Ferrante, Shaw, and Scott (2011), prostate cancer is the most common cancer and second most common cancer death among men in the United States. Early detection permits appropriate and timely management, which can allow clinicians to treat the cancer effectively. When detected at early or regional stage, prostate cancer has a five-year survival rate of about 100%. Prostate-specific antigen (PSA) is the most widely used tumor marker and was approved by the FDA in 1994 as an aid in the early detection of prostate cancer (Duffy, 2011). PSA screening helps detect prostate cancer earlier, at lower clinical stages, and with a lower Gleason score (Cho et al., 2015).

In sequence one I found that it was the protein BRCA2. This protein is responsible for repairing DNA, it is a tumor suppressor gene. A tumor suppressor helps cells from growing and dividing too quickly and out of control. BRCA2 also helps regulate cytokinesis. If something is wrong with this protein at any point, there can be a risk to develop breast, ovarian, and prostate cancer. BRCA2 is involved in the maintenance of genome stability, specifically the homologous recombination for DNA repair. More than one thousand eight hundred cases have been presented to doctors for breast cancer. It has been found to come in clusters with families, but not always. Men are at risk of prostate cancer at an early age and is said to be very aggressive. Men

Prostate carcinoma is the most commonly diagnosed cancer and the second leading cause of cancer death in men in the United States.1 Although local therapies with curative intent, such as radical prostatectomy and radiotherapy, may result in durable disease control, up to 30% of patients experience biochemical progression.2 Patients who are at a high risk for failed definitive local therapy represent ideal candidates for adjuvant therapy or for clinical trials of systemic . Patient consisted of digital rectal examination and serum PSA , which were done every 3 months for year 1, semiannually from years 2 to 5 and annually . Biochemical progression was defined as a sustained increase on 2 or more occasions of serum total PSA greater than 0.2